CD55 antibody

Catalog No. ABIN2192214

This anti-CD55 antibody is a Rat Monoclonal antibody detecting CD55 in WB and FACS. Suitable for Mouse. This Primary Antibody has been cited in 4+ publications.

Quick Overview for CD55 antibody (ABIN2192214)

Target: CD55 (Complement Decay-Accelerating Factor (CD55))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This CD55 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS)

Clone: 3D5

Product Details anti-CD55 Antibody

Sterility: 0.2 μm filtered

Application Details

Application Notes: It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Expiry Date: 12 months

References for anti-CD55 antibody (ABIN2192214)

Lin, Fukuoka, Spicer, Ohta, Okada, Harris, Emancipator, Medof: "Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies." in: Immunology, Vol. 104, Issue 2, pp. 215-25, (2001) (PubMed).

Harris, Spiller, Morgan: "Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities." in: Immunology, Vol. 100, Issue 4, pp. 462-70, (2000) (PubMed).

Spiller, Goodfellow, Evans, Almond, Morgan: "Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF." in: The Journal of infectious diseases, Vol. 181, Issue 1, pp. 340-3, (2000) (PubMed).

Spiller, Harris, Morgan: "Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells." in: Journal of immunological methods, Vol. 224, Issue 1-2, pp. 51-60, (1999) (PubMed).

Target Details for CD55

Target: CD55 (Complement Decay-Accelerating Factor (CD55))

Alternative Name: Complement Decay Accelerating Factor

Background: The monoclonal antibody 3D5 recognizes complement decay accelerating factor (DAF), also designated as CD55. Cells express on their surface several proteins which protect against complement attack, namely C receptor I (CR1), decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathways of complement by either accelerating decay of the C3 and C5 convertase (CR1, DAF), or acting as cofactors for the serine protease factor I, which cleaves and irreversibly inactivates C3b (CR1, MCP). Mouse DAF (CD55) is a 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half-life of the C3 convertases. DAF is broadly distributed among cells in contact with serum, including both haematopoietic and nonhaematopoietic cells. Although DAF does not have an essential role in controlling hemolysis of erythrocytes, it has an important role in regulation of the deposition of C3 on nucleated cells. Together with other complement regulators DAF protects self cells from autologous complement- mediated injury. DAF cooperates with CD46 in circumventing autologous C3 deposition, while CD59 inhibits the pathway at the critical end-point. DAF (decay accelerating factor), CD55 Aliases NRK cells expressing transmembrane-anchored mouse DAF Immunogen Rat IgG2a

Pathways: Complement System, Regulation of Leukocyte Mediated Immunity